<DOC>
	<DOC>NCT00621725</DOC>
	<brief_summary>To determine how patients with advanced cancer and various degrees of hepatic impairment will metabolise Cediranib.</brief_summary>
	<brief_title>Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>Written informed consent Advanced solid tumour (not prostate cancer) for which no standard therapy exists WHO performance status 02 Bilirubin levels within the target range Unstable brain/meningeal metastases Inadequate bone marrow reserve Biochemistry/haematology results outside of required ranges History of significant GI impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Advanced cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>hepatic impairment</keyword>
</DOC>